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1. Introduction 
Non steroidal anti-inflammatory drugs (NSAIDs) are the most prescribed medications 
worldwide because of their analgesic and anti-inflammatory properties. In fact, NSAIDs are 
generally prescribed for pain management in musculoskeletal or osteoarticolar pathologies 
and for rheumatic diseases, very common diseases in the general population. 
About twenty million US patients were prescribed NSAIDs every year. Although NSAIDs 
are generally well tolerated, chronic therapy is responsible for a significant morbidity and 
mortality rate; in fact, the incidence of GI events is significantly higher (about four fold) in 
patients receiving NSAIDs chronic therapy (Shaheen et al., 2006; Lawrence et al., 1998).  
NSAIDs and aspirin present a favorable benefit profile in relief from pain, inflammation 
reduction and contribute to lower the risk of cancer, as demonstrated by some 
epidemiologic and clinical studies  showing a reduced incidence of colon cancer in 
patients receiving low-dose aspirin (Din et al., 2010; Rothwell et al., 2010; Elwood et al., 
2009). 
Moreover, low-dose aspirin therapy induce a significant reduction in cardiovascular (CV) 
and cerebrovascular events and effectively lower the rate of deaths in patients with 
cardiovascular risk factors and previous CV events. On the other hand, adverse 
gastrointestinal events related to NSAIDs therapy occur in a little but significant amount of 
patients, resulting in an important morbidity and mortality; world mortality secondary to 
NSAIDs therapy has been estimated to be similar to that caused by HIV-related 
complications (Abraham et al., 2005; Laine et al., 2010). For example, in the US more than 
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100.000 patients were admitted every year for NSAIDs related  adverse events, resulting in 
about 15000 deaths (Weil et al., 2000; Ofman et al., 2002). 
Non-selective NSAIDs (nsNSAID) inhibit  both cyclooxigenase-1 (COX1) and 
cyclooxigenase-2 (COX2). These two enzyme have different roles in the cell and, in 
particular, COX1 mediates prostaglandin (PG) secretion which is one of the upper GI 
protective mechanisms. That is why, with the aim of reducing NSAIDs related upper GI 
toxicity, selective COX2 inhibitors (coxibs) were developed in the last decade. Coxibs 
weakly inhibit COX1 and a reduced relative risk of developing upper GI injury was 
demonstrated in clinical trials in patients receiving coxibs. 
2. Epidemiology 
The incidence of peptic ulcer disease is tightly related to epidemiological changes in 
environmental factors, reflecting aging, prevalence of  Helicobacter pylori infection and use of 
NSAIDs. 
Non-steroidal anti-inflammatory drugs (NSAIDs) are estimated to be the most prescribed 
therapy worldwide (Clinard, 2001); unfortunately, chronic NSAIDs therapy may induce 
upper gastrointestinal injury, leading to symptoms such as dyspepsia, chest pain or 
heartburn or severe complications (i.e. gastroduodenal ulcers bleeding or perforation). 
The incidence of GI injuries is significantly higher (about four fold) in patients receiving 
NSAIDs chronic therapy and 1-2.5 clinically significant adverse events were recorded for 
100 patients treated/year; it was estimated that 20-40% of patients receiving chronic 
NSAIDs therapy present endoscopic finding of gastroduodenal mucosal injury (MacDonald, 
1997; Ramey, 2005; Targownik 2006; Taha, 1996). All these evidences, lead to an increased 
mortality of patients receiving NSAIDs.  
Moreover, these adverse event rates, resulting from observational studies, refer to general 
population receiving NSAIDs; when clinical studies evaluate high-risk categories, the relative 
risk for upper GI events significantly increase. Therefore, the available guidelines identify 
these high-risk categories of patients and try to outline possible specific management strategies 
for each category (Anon, 2000; Lanza, 2009; Moens, 2004; MacLean 2001). 
Different guidelines identify various risk factors for the development of upper GI injury 
under NSAIDs therapy: age, previous history of an upper GI event, the need of high-dose 
NSAIDs, Helicobacter pylori infection, use of antiplatelet agents, use of warfarin or other 
anticoagulant agents, corticosteroids, selective serotonin re-uptake inhibitors (SSRI), and 
alendronate (Langman 1994; Garcia Rodriguez 1994; Papatheodoridis, 2006; Huang, 2002). 
On the other hand, GI risk factors in patients receiving coxibs are not well defined, with a 
significant lack of data: only a previous history of peptic disease or ulcer bleeding, presence 
of Helicobacter pylori infection and concomitant assumption of antiplatelet agents are 
considered independent risk factors (Lanas, 2005). 
In order to minimize NSAID-related events, evidence-based guidelines suggest to prescribe 
coxibs or a gastroprotective agent combined to a nsNSAID to high risk patients (Lanza, 2009). 
The first drug registered as a gastroprotective agent, in patients receiving NSAID, was 
misoprostol, a PG analogue. Clinical studies assessed the efficacy of misoprostol in reducing 
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the onset of gastroduodenal injuries in patients receiving chronic NSAIDs therapy; however, 
misoprostolis poorly tolerable. Effective doses of misoprostol induce dyspepsia and are often 
associated to development of diarrhea and abdominal pain/bloating while low doses do not 
induce side effects but are ineffective as gastroprotection (Lanza, 1989; Targownik, 2008). 
Other recent and effective therapies were developed in order to reduce upper GI symptoms 
and prevent complications: histamine-2 receptor antagonists (H2RAs) and proton pump 
inhibitors (PPI) have both demonstrated efficacy in NSAID-related GI side effects (Hawkey, 
2005; Hooper, 2004; Rostom, 2002; Scheiman, 2006). 
During chronic NSAIDs therapy, a significant amount of patients present with dyspeptic 
symptoms; however, development of GI symptoms is not predictive for development of 
NSAID-related injury (gastropathy or ulcers). Moreover, about 60% of patients with 
endoscopic findings of NSAID-related injury do not present GI symptoms until bleeding or 
perforation occur. Finally, only 10% of NSAID-related injury become symptomatic for 
hemorrhage (Somerville, 1986). 
Pathophysiology of NSAIDs peptic ulceration: Defense and injury mechanisms 
Defense mechanisms 
The gastroduodenal mucosa is continuously exposed to endogenous (HCl, pepsin and bile 
acids) and exogenous (drugs, alcohol and bacteria) noxious agents; therefore, upper GI tract 
is characterized by a complex biological defense system, in order to prevent and heal any 
injury. 
Pre-epithelial, epithelial and post-epithelial defenses were together involved in this complex 
mechanism preventing mucosal injury and maintaining integrity. The pre-epithelial defense level 
consists of mucus and a bicarbonate barrier, secreted by upper GI epithelial cells. Mucus is 
composed by water (95%), lipids (fatty acids and phospholipids) and glycoproteins (mucin), 
and constitutes an hydrophobic layer preventing ions and molecules (eg. pepsine) passage. 
Bicarbonate, directly secreted into the mucus layer, forms a high pH gradient (6-7) able to 
neutralize lumen acidity even when pH falls below 2. The epithelial defense layer is constituted 
by a continuous layer of GI epithelial surface cells linked to each other by tight junctions, these 
complexes constitute an hydrophobic barrier limiting the diffusion of hydrogen ions and 
water-soluble agents through the mucosa; moreover, hydrogen ions that enter into the 
epithelial cells can be removed by basolateral ion pumps (i.e. Na+/H+ and a Cl-/HCO3- 
exchanger). Minimal mucosal injury can be rapidly recovered thanks to the migration of the 
nearest healthy cells able to close the mucosal gap, a phenomenon known as rapid restitution. 
This event involves several growth factors such as epidermal growth factor (EGF), transforming 
growth factor alpha (TGFα) and fibroblast growth factor (FGF). Rapid restitution involves only cell 
migration not cell division so that only minor mucosal defects can be healed; large peptic 
lesions requires cellular proliferation and neoangiogenesis (regeneration). The rich vascular 
system that underlies the mucosa represents the post-epithelial defense mechanism. Blood flow 
continuously provides bicarbonate to neutralize the acids released and supplies nutrients and 
oxygen essential for cells metabolism while  taking away all the toxic catabolites produced. 
(Malfertheiner, 2009; Laine, 2008). 
GI injury occur when the caustic acid-peptic factors on gastrointestinal lumen overwhelm all 
three components of epithelial defense or when those mechanisms are impaired. 
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Injury mechanisms 
NSAID-induced upper GI injury result from both topical damage and systemic effects 
mainly related to COX inhibition. Topical injury is a direct consequence of the chemical 
proprieties of these drugs. NSAIDs are weak acids that remain in non-ionized lipophilic 
form in the highly acid gastric environment. This condition promote the NSAIDs migration 
through the hydrophobic cell membrane into the cell where, because of the neutral pH, they 
get trapped inside in an ionized form (ion trapping). The resulting hydrogen ions are 
responsible of cellular toxicity; oxidative phosphorylation is compromised with impaired 
mithocondrial energy production, reduced cellular integrity and increased permeability. All 
these changes, lead to retrodiffusion of H+ and pepsin with consequent amplification of 
cellular toxicity (Sostres C., 2010). 
Topical injury was once thought to be the main mechanism of NSAID-induced damage, but 
it is now clear that most of the NSAID-related gastrointestinal injuries come from their 
systemic effects; NSAID-related inhibition of GI mucosal cyclooxygenase, regardless of the 
drug administration modality, could lead to clinically significant GI toxicity. 
Cyclooxigenase converts arachidonic acid into active prostaglandins (PGs); in humans (at 
least) two isozymes of COX were described, COX-1 and COX-2 (Wallace et al., 2000). These 
two isoforms present different characteristics of expression in human cells and substrates: 
COX-1 is almost ubiquitary and necessary for cellular homeostasis (gastric protection, 
vascular regulation, platelet aggregating effect and kidney function), while COX-2 is 
expressed in cells exposed to inflammatory signals (cytokines or chemokines) or growth 
factors. 
Gastric cells COX-1 is the rate-limiting enzyme in PGs biosynthesis; these molecules 
guarantee the mucosal coating protection from the caustic action of acid and pepsin in many 
ways. First of all, PGs reduce gastric acid secretion and stimulate the production of 
glycoprotein (mucin), bicarbonate and phospholipid by epithelial cells. Moreover, PGs 
guarantee mucosal blood flow and oxygen delivery through vasodilatation, promote 
epithelial cells migration towards the luminal surface during restitution and finally enhance 
cells proliferation (Brzozowski, 2008; Sostres, 2010).  
Most of nsNSAIDs inhibit both COX-1 and COX-2, leading to a strong impairment of gastric 
PG biosynthesis; therefore, in the last decades, research interest was focused on the 
development of new molecules with a COX-2 selective inhibitory effect, in order to obtain 
an effective anti-inflammatory effect and preserve PG-mediated gastrointestinal mucosal 
protection. (Malfertheiner, 2009; Laine, 2008). 
First trials evaluating coxibs GI safety profile (Laine, 1999) were very promising; rofecoxib 
appeared to be safer than ibuprofen with a reported GI event rate similar to that observed in 
the placebo group. 
However, the initial enthusiasm secondary to coxibs’ GI safety was put in perspective 
because of the evidence of serious CV side effects (hypertension, edema, hearth failure 
and acute coronary syndrome) that, in some cases, brought to their withdrawal from the 
market (rofecoxib, precoxib and valdecoxib). Coxibs, when given at clinically effective 
doses, present a significantly reduced but still effective COX-1 inhibitory effect leading to 
a blockade of gastrointestinal mucosal COX-1-dependent PGs production: therefore, 
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coxibs significantly reduce, but do not completely abolish, the risk of gastrointestinal 
events. Moreover, as observed with nsNSAIDs other than naproxen, coxibs increase CV 
risk because of their pro-aggregating action; the selective inhibition of COX-2 create a 
disequilibrium between endothelial synthesis of PGs (mostly COX-2 dependent) and the 
platelets TxA2 synthesis (COX-1 dependent), with relative increased activity of the latter 
(Antman, 2005). Coxibs are now strongly contraindicated in patients with CV disease 
(Abraham, 2010; Bhatt, 2008). Finally, the evidences that COX-2 is considerably expressed 
in the proliferating zone of gastric mucosa undergoing mucosal repair or regeneration 
during ulcer healing, suggest that COX-2, although being of lesser significance in resting 
conditions, possess a crucial role in processes of mucosal repair and ulcer healing 
(Brzozowski, 2008). 
The impairment of mucosal microcirculation should be considered one of the most 
important mechanism of damage that results from NSAIDs consumption. It originate both 
from the PGs inhibited biosynthesis and, at the same time, from the phlogosis that brings to 
leukocytes recruitment, activation and endothelial-adherence. An answer to this key source 
of mucosal injury has been found in nitric oxide (NO). Thanks to NO vasodilatatory activity 
mucosal defense mechanisms, including mucus/alkaline secretion and inhibition of 
leukocytes activation, result enhanced. CINODs (COX-inhibiting NO-donating drugs), a 
new class of anti-inflammatory compounds putting its conceptual basis on the protective 
action of NO, appear to preserve their anti-inflammatory proprieties with a greater 
gastrointestinal safety (Brzozowski, 2008). Several CINODs are currently being tested in 
clinical trials, the most advanced of which regards naproxcinod (NO-naproxen, 
nitronaproxen) that is in phase III trials for the treatment of osteoarthritis. 
Aspirin 
Acetylsalicylic acid (ASA), the first molecule studied for its anti-inflammatory properties, 
presents various effects; the mechanisms underlying these effects appear to be related to the 
doses: low doses (< 80 mg/day) induce an acetylation of cyclooxygenase-1 in an irreversible 
way, leading to antithrombotic effect; medium doses (650 mg - 4 g/day) block prostaglandin 
production through an inhibition of both COX-1 and COX-2; higher doses ( > 4g/day) 
induce an anti-inflammatory effect through both a cyclooxygenase-dependent and a COX-
independent way (Lauer, 2002). Most of aspirin effects, like non-salicylate NSAIDs, are 
mediated by inhibition of cyclooxigenase active site of PGH2 (prostaglandin synthase H2).  
Aspirin acts through an irreversible inhibition of both COX isoenzymes, impairing PG 
production. Inhibition of COX-1 is about 10-fold greater than COX-2 ones; on this basis, the 
dose necessary to achieve an anti-inflammatory effect is significantly higher than antiplatelet 
dose and GI toxic dose. 
Moreover, aspirin inhibits (although not completely) the expression of iNOS (inducible 
Nitric Oxide Synthase) independently from COX-inhibition; this effect leads to an impaired 
production of nitric oxide, a molecule responsible for inflammatory response, host defenses 
and tissue healing process. This partial COX-independent suppression of NO production 
lead to a synergistic anti-inflammatory effect (coupled with COX inhibition) induced by 
ASA, but also to a synergistic GI toxic effect with both nsNSAIDs and coxibs.  
Moreover, aspirin GI toxicity, is worsened by its topic injury due to the rapid absorption of 
this drug from the stomach (low PKa) that result in an enhanced local gastric toxicity. 
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Finally, the use of acetylsalicylic acid, even if prescribed at low doses, seems to abolish the 
GI safety profile of coxibs. Although the use of a COX-2 selective inhibitors could lead to a 
significant decrease in GI adverse events, when coxibs are prescribed together with aspirin 
the overall GI toxicity appear to be similar to that observed with standard NSAIDs 
(Silverstein,  2000). 
Role of Helicobacter pylori infection 
Although GI injury (peptic ulcers or erosive gastropathy) is the most frequently observed 
side effects in patients on chronic NSAIDs therapy, presence of Hp infection is the most 
common cause of peptic disease in patients not on NSAIDs therapy. It was estimated that 
chronic Hp infection was present in about 50% of the population worldwide; however, only 
a little amount of these patients (5-10%) will develop GI injuries. Risk factors for 
development of Hp-related peptic ulcers are not well understood; however, different 
histological pattern of gastritis, change in acid secretion, the presence of duodenal gastric 
metaplasia, ulcerogenic bacterial strains and host genetic factors are all involved. For 
example, the relative risk to present peptic ulceration is increased in patients  infected by the 
CagA-positive bacterial strain (Pilotto, 1997; Covacci, 1993; Li, 1999; van Doorn, 1998; Garcia 
Rodriguez, 1994; Huang, 2002). 
3. Management of NSAIDs therapy 
In order to reduce the incidence of GI complications among patients receiving chronic 
NSAIDs therapy, various management strategies were developed (prevention strategy, 
identify and treat modifiable risk factors, use of gastroprotective agents, use of “low-risk” 
NSAIDs ) 
General prevention strategies 
Prevention strategies have to be followed by all patients receiving long-term NSAIDs 
therapy; crucial point is to stratify patient's risk (both gastrointestinal and cardiovascular). 
Some general rules have to be kept in mind by physicians who prescribe NSAIDs: use the 
“safer” NSAID at the lowest effective dose and for the shortest period of time (see Table 1 
for relative GI toxicity of NSAIDs); when possible, prescribe anti-dolorific drugs other than 
NSAIDs (i.e. acetaminophen, tramadol or codeine). Avoid concomitant therapy, when 
possible, with antiplatelet agents, anticoagulants or corticosteroids; suggest to the patients to 
avoid physical (and psycological) stress and reduce (or avoid) smoke and/or alcohol 
assumption (Lanza et al., 2009). 
Prescription of selective COX2  inhibitors 
The anti-dolorific, anti-inflammatory and chemo-preventive effects of NSAIDs are mediated 
by inhibition of COX. The development of an NSAID selectiveely inhibiting the COX-2 
isoform was reached in order to avoid NSAID-related GI toxicity. Coxibs appear to be 200 to 
300-fold more selective for COX-2 than COX-1. 
The active effects of coxibs are similar to those observed with nsNSAIDs but with a better GI 
safety profile (based on the reduced inhibition on COX-1 dependent prostaglandins 
secretion in upper GI tract). However, these benefits are balanced with the well reported 
increased CV risk observed in long-term users; the registration trials of coxibs (rofecoxib and  
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Drug Dose RR 
Acetaminophen < 2000 mg 1.2 
 2000 – 3900 mg 1.2 
 > 4000 mg 1.0 
Ibuprofen < 1200 mg 1.1 
 1200 – 1799 mg 1.8 
 > 1800 mg 4.6 
Diclofenac < 75 mg 2.2 
 75 – 149 mg 3.2 
 > 150 mg 12.2 
Piroxicam < 10 mg 9.0 
 10 – 19 mg 12.0 
 > 20 mg 79.0 
Table 1. Dose-dependent risk for Upper GI bleeding (Acetaminophen and ns-NSAIDs) 
Dose-dependent risk for Upper GI bleeding (Acetaminophen and ns-NSAIDs) 
subsequently valdecoxib) reported an alarming increase of CV events (congestive heart 
failure, polmunary edema and myocardial infarction), leading to withdrawal from market of 
both drugs (Juni et al., 2004; Abraham et al., 2007). 
Currently, this  new drug generation accounts for about 33% prescription (60% of the 
relative healthcare expenditure). Initially, a completely safe profile of coxibs was speculated 
based on preclinical and clinical trial, even for high risk patients (Skelly and Hawkey, 2002). 
However, these benefit effects were initially demonstrated only in patients without GI risk 
factors. The incidence of GI events in patients with one or more risk factors was similar in 
those receiving coxibs or nsNSAIDs (Silverstein et al., 2000; Bombardier et al., 2000; Skelly 
and Hawkey, 2002; Farkouh et al., 2004). 
Clinical trials demonstrated that coxibs have a reduced relative risk of development of 
peptic ulcers and other GI complications (Hooper et al.,2004); in fact, a significant reduction 
in ulcers found on endoscopy studies (about 4-fold reduction) was observed (FitzGerald and 
Patrono, 2001),. High doses of coxibs (rofecocix or celecoxib) allow an approximately 50% 
reduction in the incidence of GI injury when compared to nsNSAIDs (Bombardier et al., 
2000). Coxibs present a reduced but not abolished GI toxicity when compared to nsNSAIDs. 
For example, patients receiving Rofecoxib present an  increased risk for peptic ulcer 
bleeding when compared to patients receiving placebo (0.88 vs. 0.18 clinically significant 
events registered/year; relative risk 4.9) (Lanas et al., 2007).  
Moreover, coxibs do not show advantages over nsNSAIDs in healing ulcers in patients with 
recent bleeding, because they inhibit the natural healing process of peptic ulcers (Perini et 
al., 2003).  
In addition, clinical evidences showed that all GI benefits of coxibs disappear in patients 
receiving also low-dose aspirin (i.e. for CV primary prevention) (Schnitzer et al., 2004; 
Farkouh et al., 2004). Moreover, when coxibs are used in combination to antiplatelet agents 
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other than low-dose aspirin (i.e. clopidogrel and ticlopidine), the relative risk of upper GI 
bleeding was similar to patients receving aspirin alone or nsNSAIDs. Finally, the 
combination of coxibs to low dose aspirin appears to attenuate its CV protective effects. 
Recently, a large prospective trial, was conducted in order to assess the safety profile of 
celecoxib compared to a combination regimen of a non-selective NSAID plus PPI 
(omeprazole plus diclofenac) (Chan et al., 2010); results of this randomized controlled trial, 
enrolling more than 4400 patients, demonstrated a reduced risk of GI adverse events of 
COX-2 selective treatment when compared to a nsNSAID plus a PPI regimen. 
Based on clinical trial experience (Chan et al., 2007), co-therapy with coxibs plus PPIs could 
be considered in those patients with exceptionally high risk of peptic ulcer disease (eg recent 
NSAID-related ulcer bleeding) in order to significantly reduce the risk of development of GI 
injury or re-bleeding. 
In conclusion, use of coxibs is a valuable strategy to minimize upper GI events; however, 
because of the increased CV risk and the reduced GI benefit in patients receiving antiplatelet 
agents, the use of these drugs have to be carefully evaluated in some high-risk categories of 
patients (i.e. older patients on low-dose aspirin regimen for primary CV prevention, patients 
with previous CV events or with CV risk factors, etc.); for a detailed discussion, see the 
specific section in this chapter. 
Clear indications for COX-2 selective inhibitors prescription are (Lanza et al., 2009; Jawad, 
2001): 
 Prolonged use of nsNSAIDs at the highest dose 
 Age > 65 years 
 Previous history of peptic ulcer disease 
 Co-treatment with corticosteroids or anticoagulants 
Prescription of gastroprotective agents 
The understanding of mechanisms underlying the pathogenesis of peptic ulcer disease lead, 
in the last decades, to significant development in gastroprotective treatments: 
- Prostaglandin analogues (misoprostol) were demonstrated effective in prevention of 
NSAID-induced ulcers (while no role in healing ulcers was demonstrated) 
- Anti-secretory drugs (H2RAs and PPIs) demonstrated their pivotal role in peptic ulcers 
disease preventing, healing and maintaining of remission 
- Antacids, like sucralfate and bismuth salts have no proven efficacy in healing NSAID-
related peptic ulcer 
- Antibiotic therapy and bismuth-containing compounds were recognized as indicated in 
patients with HP-positive ulcer disease (even if related to NSAIDs) 
Prostaglandins (PG) inhibit histamine-induced cAMP generation in parietal cells, leading to a 
significant reduction in acid secretion. Prostaglandin analogues are indicated mostly for the 
prevention of NSAID-related GI injury because there are no clearly demonstrated effect on 
ulcer healing. The only available PG analogue registered for NSAID-related peptic ulcer 
disease is misoprostol (Donnely et al., 2000; Silverstein et al., 2005). However, the use of 
misoprostol is limited by its low tolerability. PG analogues, in a dose-dependent manner, 
induce diarrhea associated to abdominal pain and bloating; in order to minimize these side 
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effects, misoprostol should be started at the lowest dose (100 mcg x 3 daily) and, if tolerated, 
increased to 800mcg/day. 
H2RAs (i.e. ranitidine, cimetidine) induce acid suppression through the blockade of 
histamine H2 receptors in gastric parietal cells, while PPIs (i.e. omeprazole, lansoprazole, 
esomeprazole, pantoprazole and rabeprazole) act on the H+/K+ ATPase pump, localized on 
parietal cell lumen inducing an irreversible inhibition (Kitchingman et al., 1989).  
PPIs appear to be more effective in preventing and healing NSAID-related ulcers (better 
duodenal than gastric ones) than high-doses of H2RAs because of the long-lasting inhibition 
of parietal cells acid secretion (standard H2RA doses are not effective in preventing GI 
injury) (Taha et al., 1996). Moreover, H2RA treatment could be “complicated” by 
phenomenon of tolerance which is not always observed, but could significantly reduce 
H2RA-induced acid suppression. Although the tolerance phenomenon is not observed in 
patients receiving PPIs, a rapid metabolization in some patients (rapid acetylators) may 
reduce PPI efficacy. Therefore, standard PPI therapy may sometimes not be sufficient to heal 
ulcers or treat NSAID-relate dyspepsia and in those cases an higher dose or a different PPI 
may be needed. 
Finally, on the basis of the incomplete gastroprotective effect of H2RAs and the significant 
reduction in PPIs' cost, there is no reason to prescribe H2RAs for gastroprotection in patients 
receiving chronic NSAID therapy; since H2RAs could mask warning symptoms of peptic 
ulcer disease (Singh and Rosen Ramey, 1998) their use should be limited to patients with 
NSAID-related dyspepsia unresponsive to PPI and with a negative upper GI endoscopy. 
Table 2 summarizes key-points regarding PPI gastroprotective effects. 
 
Evidences on PPI gastroprotection 
- reduced risk of NSAID-related upper GI injuries 
- effective in preventing ulcer complications 
- strongly recommended in patients with high GI risk 
- comparable to coxibs in high-risk patients  
- superior to Coxibs in reducing and preventing NSAID-related dyspepsia 
- effective in prevention of upper GI events in patients receiving antiplatelet agents 
- effective in healing and preventing upper GI ulcers in patients on chronic NSAID therapy 
Table 2. Evidences on PPI gastroprotection 
Antacids (containing aluminium or magnesium) are not clearly effective in preventing or 
healing NSAID-related ulcers and their potential healing mechanism appear to be unrelated 
to acid inhibition (i.e. promotion of angiogenesis, binding bile acids, suppressing Hp 
growth): sucralfate increase angiogenesis and tissue repair leading to prevention of mucosal 
injury; bismuth salts act through the inhibition of peptic activity. 
4. Management of specific populations 
Management strategies are designed to reduce the incidence of GI complications and take 
into account patient's overall risk and specific NSAID-related risk factors. Most guidelines 
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describe specific strategies for high-risk categories of patients; designed to significantly 
reduce side effects (both general and gastrointestinal) and the number needed to treat 
(NNT) to achieve the endpoints (reduction in GI events). These strategies often involve the 
prescription of a gastroprotecive agent (PPIs), reduction of nsNSAIDs dose and the change 
to selective COX-2 inhibitors. 
Management of low-risk patients 
Most guidelines do not suggest gastroprotective strategies for low-risk patients. Physicians 
prescribing NSAIDs to low-risk patients (less than 65 years, no comorbidity, no concomitant 
antiplatelet, anticoagulants or corticosteroids and no previous history of NSAID-related GI 
complications) should follow the general suggestions for GI complications reduction (eg. 
prescribe the lowest effective dose and avoid drugs with high GI toxicity). 
However, even in patients without risk factors, two clinical trials demonstrated a significant 
reduction of GI events (detection of asymptomatic ulceration and bleeding) in patients 
receiving coxibs compared to those on nsNSAIDs (Bombardier et al., 2000; Silverstein et al., 
2000); these evidences suggest that the low-risk category of patients could become a “no-
risk” one, if well managed. 
Patient with history of peptic ulcer disease 
Epidemiological and retrospective studies identified a past episode of peptic ulcer as a risk 
factor for development of GI events in patients receiving chronic NSAID therapy; moreover, 
both Hp positive and negative patients present an increased relative risk of complications 
(Rockal et al., 1995). In order to reduce the risk of GI injury, the switch to a coxib was 
evaluated in patients with a past history of ulcer disease; both rofecoxib and celecoxib 
demonstrated their efficacy in reduction of GI events (from 8.8/100 patient/year with non 
selective NSAID to 2 with rofecoxib) (Laine, 2001). Therefore, in patients with a previous 
history of peptic ulcer disease, the switch to a selective COX-2 inhibitor could be considered 
a practical and cost-effective strategy. 
Although switching to a coxib induces a significant risk reduction, in these patients there is 
still a high residual risk of development of GI complications (10 events per 100 patients 
treated/year in VIGOR study) (Bombardier et al., 2000). In this setting, the combination 
therapy of a PPI to a standard NSAID appears to be more appropriate than a coxib alone; 
clinical studies demonstrated that combination with omeprazole induces a significant 
reduction in ulcer development both in patients with previous ulceration and perforation 
when compared to patients receiving a COX-2 selective inhibitors (rofecoxib) or 
monotherapy with ns-NSAID (ibuprofen) [Cullen et al., 1998; Hawkey et al., 1998). After this 
first evidence, PPIs other than omeprazole (both lansoprazole, pantoprazole and 
esomeprazole) demonstrated a similar efficacy (Yeomans et al., 1998; Hawkey et al., 1998; 
Agrawal et al., 2000) in preventing NSAID-related bleeding (a mean reduction of at least 
four-fould). 
Subsequently, in patients with previous GI complications, usually considered to be at 
exceptionally high risk of GI events, a combined treatment of a coxib with a PPI was 
proposed in order to reduce GI toxicity. This strategy was evaluated in a RCT comparing the 
combination therapy of celecoxib plus PPI to celecoxib plus placebo in Hp negative patients 
who presented an upper GI bleeding. The addiction of a PPI to a COX-2 selective inhibitor 
www.intechopen.com
Chronic NSAIDs Therapy and Upper Gastrointestinal Tract – Mechanism of Injury,  
Mucosal Defense, Risk Factors for Complication Development and Clinical Management 
 
159 
was demonstrated effective for prevention of ulcer re-bleeding (13-month incidence of 0% 
vs. 8.9% in patients treated with celecoxib alone) and considered the best treatment 
management in the very high risk group of patients (Chan et al., 2007). 
Patients requiring high-doses NSAIDs 
When physicians have to prescribe high NSAID doses, there is a significant increase in the 
relative risk of development of GI complications (about three-fold).(Henry et al., 1996; 
Langman et al.,  1994). In those cases, pharmacological and clinical evidences demonstrated 
that coxibs are safer than nsNSAIDs with a similar anti-inflammatory and analgesic effects. 
However, high-doses of coxibs show an overall increased risk of adverse events (both CV 
and related to fluid retention) and this should be taken into account in each single case to 
balance the risk/benefit ratio.. 
Helicobacter pylori positive 
Large population-based studies and meta-analysis demonstrated that Hp infection induce a 
two-fold increase in the risk of developing peptic complications in patients receiving 
NSAIDs (Chan et al., 2002; Vergara et al., 2005). Moreover, also in patients receiving coxibs, 
H pylori remain a risk factor for development of GI ulcers and bleeding (Bombardier et al., 
2000). Systematic reviews and meta-analysis (Chan, 1997; Chan 2002; Vergara 2005) 
confirmed the efficacy of Hp eradication in preventing upper GI complications in patients on 
chronic NSAIDs therapy, even though treating Helicobacter pylori does not completely 
abolish the risk of bleeding in high risk patients (Chan, 2001). Therefore, even though it is 
often underestimated in general clinical practice, a test-and-treat strategy is mandatory in 
patients who require long-term NSAIDs therapy (Gabriel, 1991; Wolfe, 1999; Sauerbaum, 
2002; Barkin, 1998; Laine, 2002; Chan, 2002; Laine, 1992; Hawkey, 1998; Loeb, 1992; 
Aalykke,.1999; Cullen, 1997).  
Patients on corticosteroids 
Corticosteroids have a synergistic effect with NSAID, magnifying their GI toxicity, and an 
intrinsic gastrolesive potential effect, specially in patients with multiple concurrent diseases; 
the risk of ulcer development is increased both in patients receiving NSAIDs and in non-
NSAID users. A correct strategy, for the management of patients who need both 
corticosteroids and NSAIDs was suggested by post-hoc analysis of large clinical trials, 
showing that prescription of coxibs seems to reduce the risk of GI complications.  
When prescribing NSAIDs to patients requiring high-doses of corticosteroids, a 
management strategy able to guarantee a reduced GI risk seems to be the choice of a coxib 
coupled by gastroprotection with a PPI; however, specific data in this setting are lacking 
(Holvoet et al., 1991; Hochain et al., 1995; Laine et al., 2010; Weil et al., 2000). 
Use of anticoagulant agents or patients affected by coagulopathy 
Co-prescription of anticoagulants and NSAIDs induce a significant increase in GI events and 
bleeding (both clinically manifest and occult); consequently, in these patients NSAID 
prescription should be considered a contraindication. Although there is a lack of specific 
data, in those patients when necessary, the co-prescription of a selective COX-2 inhibitor 
plus a PPI have to be considered in order to reduce the high risk of bleeding and the high 
morbidity and mortality that goes with it. 
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5. Management of NSAID prescription and gastroprotective strategies in 
patients with both CV and GI risk factors 
The greatest intellectual and clinical challenge in the area of NSAID-induced GI injury is the 
management of patients with both gastrointestinal and cardiovascular disease; a tight 
correlation between GI bleeding and CV disease (and related treatment) is well recognized 
(Hallas et al., 2006). Most of these events appear to be related to antiplatelet and/or 
anticoagulant agents prescribed in those patients (Pearson et al., 2002; McQuaid and Laine, 
2006; Derry and Loke, 2000; Peters et al., 2003). Even though, in epidemiologic studies, 
presence of CV disease appear to be an independent risk factor for ulcer bleeding, not 
related to aspirin and anticoagulant agents use (Weil et al., 2000). 
For a complete discussion of the pathogenesis of NSAID-related (including aspirin) GI 
injury see specific section of this chapter. However, both NSAIDs and ASA through topic 
and systemic effects induce mucosal injury.  
Clopidogrel, through a specific inhibition of platelet aggregation, play a pivotal role in 
impairment of ulcer healing process; in fact, platelet aggregation and angiogenesis are both 
critical for healing of GI injuries. Therefore, even if clopidogrel may not be the primary 
cause of gastroduodenal injury, its related impairment of mucosal healing and angiogenesis 
could lead to clinically significant ulceration in the presence of other co-factors (eg. excessive 
acid exposure, other drugs or Hp) (Ma et al., 2001). 
Patients with CV co-morbidities, requiring NSAIDs for their anti-inflammatory or analgesic 
effects (i.e. rheumatoid arthritis, muscle-skeletal disease, etc.) present an increased GI risk 
and are exposed to an increased rate of systemic hypertension secondary to NSAIDs or 
coxibs use (Lanas et al., 2000; Antman, 2005). The management of these patients is based on 
the assessment of the risk/benefit ratio of every drug prescribed. In patients on secondary 
prophylaxis for myocardial infarction or cerebrovascular event, prescription of antiplatelet 
agents (aspirin or clopidogrel or both) is mandatory and also some high-risk CV patients 
would benefit from a low-dose aspirin prophylaxis; in such cases, especially in those with 
GI risk factors, the prescription of a gastroprotective agent appear to be useful and effective 
in reducing adverse events. 
It has be kept in mind that, coxibs and nsNSAIDs might be associated with an increased risk 
of acute cardiovascular events, and that co-administration of an NSAID (ibuprofen) and 
aspirin reduce the antiplatelet effects and consequently the prophylactic efficacy. Data are 
lacking about the consequences of co-administration of coxibs and aspirin on 
cardioprotection.  
Finally, in this setting, presence of CV co-morbidities or assumption of prophylactic low-
dose aspirin should be considered a contraindication for NSAIDs prescription; in those case 
in which appear necessary, general prescription strategies designed to reduce the adverse 
events rate have to be kept in mind (see specific section in this chapter).  
Gastroprotective strategies in patients with CV disease 
When a physician approaches a patient who need NSAID therapy with CV and GI disease, 
there are some considerations to take in mind in order to reduce adverse events related to 
co-morbidities: 
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 Aspirin induce a 2- to 4-fold increase in risk of development of GI injury with a dose-
dependent effect; therefore <80 mg/day should be preferred coupled to 
gastroprotection.  
 When prescription of low dose of aspirin is associated to NSAIDs a gastroprotective 
strategy should be offered. 
 PPIs are demonstrated as the most effective gastroprotective agents in patients 
receiving both NSAIDs and aspirin (Lai et al., 2002) 
 When aspirin or clopidogrel (or both) are prescribed together with anticoagulant agents 
(heparin, fractionated heparin or oral anticoagulant) a significant increase in upper GI 
bleeding risk is observed. Combination of antiplatelet and anticoagulant agent must be 
prescribed only with a clear indication (vascular, valvular or arrhythmic). In order to 
reduce the overall bleeding risk (both extracranial and intracranial) when warfarin is 
co-administered to aspirin, INR must be < 2.5 (Andreotti et al., 2006; Zhurram et al., 
2006). 
 In high-risk patients, ASA and non-ASA antiplatelet agents (ticlopidine and 
clopidogrel) present similar bleeding risk, therefore, switching aspirin to clopidogrel do 
not reduce GI events (Chan et al., 2005). 
Gastroprotective strategies in patients receiving clopidogrel 
Dual anti-platelet therapy (low-dose aspirin plus clopidogrel), prescribed to patients for 
secondary prevention of acute coronary syndrome or undergoing coronary stent 
implantation, is effective in preventing stent thrombosis and reducing the risk of re-
infarction, but  significantly increase the risk of GI bleeding. The relative risk increase to 
about 2.5-fold in patients receiving clopidogrel or ASA, when compared to patients not on 
antiplatelet agents (Ibanez et al., 2006; van Hecken et al., 1998; Delaney et al., 2007). Use of 
clopidogrel in aspirin-taking patients synergistically increase the risk of bleeding (2- to 3-
fold) and the mean blood loss in case of haemorrhage (Yusuf et al., 2001; Connoly et al., 
2009). Dual antiplatelet agents are not indicated for CV primary prevention because of the 
observed low reduction in CV events and significant increase in severe GI bleeding. 
Clopidogrel, as discussed above, does not induce ulceration of upper GI tract, but impairs 
natural healing process (through inhibition of platelet attivation and aggregation) and 
increases bleeding from preexisting lesions (induced by other causes). As in NSAID-related 
GI bleeding, acid suppression could favors the healing process and stabilization of thrombi 
thereby reducing the rate of complications from upper GI injury (Ma et al., 2001).   
Acid suppressive therapy (both H2RAs and PPIs) demonstrated its efficacy in reduction of 
bleeding risk related to antiplatelet therapy. H2RAs appear to be able to reduce the rate of 
GI adverse events in patients receiving low-dose aspirin (3.8% in famotidine-receivers vs. 
23.5% of placebo ones) (Taha et al., 2009) while no reduction was found in those treated with 
clopidogrel (Lanas et al., 2007). PPIs resulted to be more effective than H2RAs in reducing 
upper GI events in a cohort of patients receiving both aspirin and clopidogrel (OR:0.04 of 
PPI-receiving vs 0.43 of H2RA-receiving) (Ng et al., 2008).  
After the evidence of the positive effects of PPI prescription in reducing GI adverse events 
among clopidogrel-receiving patients, some observational studies suggested the presence of 
a possible interaction between clopidogrel and PPI determining a reduced antiplatelet effect 
(Ho et al., 2009; Juurlink et al., 2009). Moreover, in vitro studies (assessing platelet 
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activation/activity as a surrogate marker of antiplatelet effect) confirmed this hypothesis of 
interaction. 
Clopidogrel and PPIs (mostly omeprazole) share a common metabolic pathway: clopidogrel 
is a pro-drug, whose bioavailability is dependent from intestinal absorption (ABCB1-
dependent) and liver metabolism (through cytochrome P-450 pathway). Clopidogrel 2-step 
activation in the liver is secondary to CYP2C19 and CYP3A activity. Most of the PPIs 
available (omeprazole, lansoprazole and rabeprazole) share the same hepatic pathway 
through CYP2C19 (Li et al., 2004). Among PPIs, pantoprazole is the only that do not 
significantly inhibit hepatic CYP2C19 at therapeutic doses, because it is mostly metabolized 
through CYP3A4 pathway, while the other PPIs available present a lower interaction with 
this isoenzyme (Ishizaki and Horay, 1999). 
Co-prescription of clopidogrel and PPIs may result in a competition of CYP2C19 
metabolism, with reduced transformation of clopidogrel in its active form (Roden and Stein, 
2009). This hypothesized impairment was additionally supported by the finding of genetic 
polymorphisms associated in CYP2C19 activity (Mega et al., 2009; Singh et al. 2010; Ma et 
al., 2010; Tiroch et al., 2010) and with a reduced antiplatelet activity and a worse clinical 
outcome (CV adverse events and re-infarction). Early clinical prospective studies in humans 
demonstrated a negative effect of omeprazole on surrogate clinical endpoints (ex vivo 
platelet assay, vasodilatator-stimulated phosphoprotein  VASP) while other PPIs 
(pantoprazole and esomeprazole) did not (Gilard et al., 2008; Cuisset et al., 2009; 
O'Donoghue et al., 2009; Siller-Matula et al., 2009). 
Based on conflicting data emerging from observational studies biased by non uniform 
prescription behaviours (eg. PPIs could be prescribed mainly to  high-risk patients), a 
randomized controlled trial was designed enrolling patients receiving both aspirin and 
clopidogrel in order to evaluate the CV safety profile of omeprazole, the COGENT study 
(Bhatt et al., 2010). The results of this trial, enrolling 3761 patients who had acute coronary 
syndrome or underwent coronary stent placement, did not found any different CV 
outcome (myocardial infarction, stroke, coronary artery bypass graft or CV death) in 
patients receiving omeprazole when compared to those receiving placebo (Hazard Risk: 
0.99), while confirming a reduced risk of GI adverse events (Hazard risk: 0.34). However, 
this strong evidence is limited by the premature closure of this trial (both enrollment and 
follow-up) due to bankrupt of the sponsorship, significantly limiting the power of the 
conclusion. 
Keypoint I - Difference between PPIs in clopidogrel-receiving patients:  
Retrospective studies showed, in some cases, an overall increased CV toxicity (Rassen et al., 
2009; Ho et al., 2009; Laine and Hennekens, 2010; Ray, 2010) while others identified specific 
molecule-related effects (i.e. an increased risk for pantoprazole in nested case-control 
retrospective study of Stockl et al., 2010). On the opposite, a population-based study 
(Juurlink et al., 2009) identified an increased CV risk for all patients receiving PPIs other 
than pantoprazole. Finally, the only prospective evidence available did not identify an 
increased risk for omeprazole (Bhatt et al., 2010). However, no prospective trial (either 
published or ongoing) compared the clinical events related to different PPIs in patients 
receiving dual antiplatelet therapy. Therefore, guidelines do not suggest any 
recommendation for a specific molecule (Abraham et al., 2010). 
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Keypoint II – Timing and dosing: 
Pharmacokinetic and pharmacodynamic properties of both these drug classes suggest a 
reduced interaction if the two administrations were separated from at least 12 hours (both 
PPI and clopidogrel present a plasma half-life of less than 2 hours). However, only a 
prospective trial tested this hypothesis, using a surrogate end-point (platelet aggregation). 
Further studies, evaluating the clinical outcome, are necessary to corroborate this result. 
Until now, there is no clinical study evaluating different PPI doses. 
In conclusion, even if some observational retrospective studies suggested a small increase 
(relative risk <2) in CV adverse events, large, prospective, controlled trial are necessary to 
validate this finding. Finally, although interrupted before the designed conclusion of 
enrollment and follow-up, the only prospective RCT available suggest a non-increased CV 
risk in patients receiving omeprazole plus dual antiplatelet therapy (Bhatt et al., 2010). 
In all patients, especially in those with both CV and GI risk factors, prescription of NSAIDs, 
antiplatelet agents and gastroprotection must be based on an accurate risk/benefit analysis. 
Antiplatelet agents are necessary in patients with CV co-morbidities, specially in those with 
prior acute coronary syndrome or with a recent stent placement; however, prescription of 
aspirin, clopidogrel or both is associated with an increased risk of GI bleeding. 
 
Fig. 1. Suggested management strategy in order to minimize upper GI adverse events in 
patients receiving chronic NSAIDs therapy.  
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Fig. 2. Suggested management strategy in order to minimize upper GI adverse events in 
patients receiving antiplatelet agents. 
The need of a gastroprotection must be evaluated on the basis of GI risk factors. High risk 
patients require gastroprotection with PPIs, while low risk population receives only a small 
benefit from PPIs prescription; in this setting, the increased risk of CV adverse events, 
related to the possible interaction between PPI and clopidogrel, suggest the use of 
antiplatelet therapy without gastroprotection. 
PPIs are demonstrated to be more effective than H2RAs (Ng et al., 2010); however, although 
to a minor extent, H2RAs (other than cimetidine, because of its hepatic metabolism through 
CYP2C19) appear to be an alternative option in decreasing risk of gastric and duodenal 
ulcers (also among antiplatelet-receiving patients) (Lin et al., 2011). H2RAs, because of the 
low cost and low interaction, could be a good choice in patients with low risk for GI 
bleeding presenting peptic symptoms or NSAID-related dyspepsia. 
6. List of abbreviations 
NSAIDs, Non-Steroidal Anti-Inflammatory Drugs; COX, Cyclooxygenase; GI, 
GastroIntestinal; CV, CardioVascular; Coxib, selective COX2 inhibitor; Hp, Helicobacter 
Pylori; H2RA, histamine-2 receptor antagonist; PPI, proton pump inhibitor; HCl, 
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Hydrochloric Acid; PG, Prostaglandin; nsNSAID, non-selective NSAID; NO, Nitric Oxide; 
TxA2, Thrombooxane A2; CINOD, COX-inhibiting NO-donating drug; ASA, Acetylsalicylic 
Acid. 
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